Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL7785580 | 0.95 | TSHR (0.44) | HIF1ATSHRMAPTTRPV1ALDH1A1 | |
| Methacrylic Acid SCHEMBL3305565 | 0.95 | TSHR (0.44) | HIF1ATSHRMAPTTRPV1ALDH1A1 | |
| Methacrylic Acid SCHEMBL15392574 | 0.93 | TSHR (0.48) | HIF1ATSHRMAPTTRPV1FAAH | |
| Methacrylic Acid SCHEMBL17710379 | 0.90 | TSHR (0.39) | HIF1ATSHRALDH1A1TDP1LMNA | |
| Glutaral SCHEMBL7455889 | 0.84 | HIF1A (0.62) | HIF1ATSHRMAPTTRPV1ALDH1A1 | |
| Methacrylic Acid SCHEMBL27798927 | 0.81 | LMNA (0.44) | TSHRMAPTALDH1A1FAAHLMNA | |
| Methacrylic Acid SCHEMBL7190474 | 0.81 | ALDH1A1 (0.55) | TSHRTRPV1ALDH1A1FAAHTDP1 | |
| Glutaral SCHEMBL28754492 | 0.81 | HIF1A (0.67) | HIF1ATSHRMAPTTRPV1ALDH1A1 | |
| Glutaral SCHEMBL28252308 | 0.81 | HIF1A (0.67) | HIF1ATSHRMAPTTRPV1ALDH1A1 | |
| Nonanal SCHEMBL28634319 | 0.80 | TSHR (0.57) | TSHRMAPTTRPV1FAAHEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713314-B2 | Disubstituted diaryloxybenzoheterodiazole compounds | ENI S.P.A. (IT) | 2023-08-01 | — | — | US | disclosed |
| US-20220098185-A1 | DISUBSTITUTED DIARYLOXYBENZOHETERODIAZOLE COMPOUNDS | ENI S.P.A. (IT) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713314-B2 | Disubstituted diaryloxybenzoheterodiazole compounds | SCO2, NR3C2, CBR3 | HIF1A 2754/4885TSHR 493/4885MAPT 4820/4885 |
| US-20220098185-A1 | DISUBSTITUTED DIARYLOXYBENZOHETERODIAZOLE COMPOUNDS | SCLY, SCO2, CBR3 | HIF1A 2615/4885TSHR 720/4885MAPT 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.